SEBI censures AstraZeneca Pharma's promoter, Elliot Group for unfair trade practices in delisting plan

SEBI censures AstraZeneca Pharma’s promoter, Elliot Group for unfair commerce practices in delisting plan

Markets regulator SEBI has strongly “censured” Astrazeneca Pharma India Ltd’s promoter and Elliot Group for skilled misconduct and following unfair commerce practises in the course of the firm’s delisting plan in 2014. The regulator, in a 65-page order, stated that AstraZeneca Pharma India Ltd’s (AZPIL) promoter AstraZeneca Prescription drugs AB Sweden (AZPAB), and Elliott Group,…

Details